The amended Microsoft-OpenAI deal, announced on Monday, saw a surge in stocks following a sluggish start to the week, with Nvidia on track for a record close. The deal allows OpenAI to serve all its products to customers across any cloud provider. However, Amazon's stock was down after a big move, but this news was welcomed by Amazon CEO Andy Jassy. The company's price target was significantly cut at Leerink, reflecting competitive pressures on the oral GLP-1 Foundayo, an oral drug developed by the company. Meanwhile, Eli Lilly announced another acquisition, buying the private Ajax Therapeutics in a deal that could be worth up to $2.3 billionon. First-quarter earnings from Amazon and Microsoft are expected after the closing bell on Wednesday, along with quarterly results from Alphabet and Meta Platforms.